1. Pink Sheet
  2. >>Pathways & Standards
  3. >>Review Pathways

Reforming Accelerated Approval: Three Ideas For Congress

 
• By Michael McCaughan

Ideas to reform Accelerated Approval are likely to be debated during the reauthorization of the key US FDA user fee funding authority in 2022. Here are three suggestions for Congress to consider.

Accelerated Congress
Congress may have to move quickly on accelerated approval reform. • Source: Nielsen Hobbs; the Pink Sheet | Alamy images

Ideas to reform the Accelerated Approval pathway are certain to be debated when Congress works on finalizing the next iteration of user fee funding legislation for the US Food & Drug Administration in 2022.

The topic is almost always on the table anyway, but the controversy over the Accelerated Approval granted to Biogen, Inc./Eisai Co., Ltd

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Review Pathways

More from Pathways & Standards

US FDA Guidance Roadblock: Writing Continues, But Publication Has Slowed Or Stopped

 
• By Derrick Gingery

Cuts to the FDA’s policy and legal personnel have prevented dozens of product-specific guidances for generic drug development from being published.

Tougher Approval Standards May Follow Vinay Prasad’s Appointment To Lead US FDA’s CBER

 
• By Sarah Karlin-Smith

Industry is concerned that Prasad may make regulatory flexibility tougher to obtain for cell and gene therapy, while vaccine and public health advocates are angry about Prasad’s criticisms of US COVID-19 policies.

US FDA Expands Surprise Foreign Inspections But Loses Associate Commissioner Michael Rogers

 
• By Sue Sutter

Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.